Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Earnings
Replimune's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 2, 2027
Q3 FY2027 · estimated, before the open
Revenue, Q2 FY2027
–
EPS, Q2 FY2027
-$0.54
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Replimune's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2027ended Dec 31, 2026 | Feb 2, 2027Expected | – | – | – | – |
| Q2 FY2027ended Sep 30, 2026 | Oct 28, 2026before the open | – | – | -$0.54 | Release |
| Q1 FY2027ended Jun 30, 2026 | Aug 14, 2026before the open | – | – | – | Release |
| Q4 FY2026ended Mar 31, 2026 | Jun 29, 2026before the open | – | – | – | Release |
| Q3 FY2026ended Dec 31, 2025 | Feb 3, 2026before the open | – | – | -$0.77 | Release |
| Q2 FY2026ended Sep 30, 2025 | Nov 6, 2025before the open | – | – | – | Release |
| Q1 FY2026ended Jun 30, 2025 | Aug 7, 2025before the open | – | – | -$0.95 | Release |
| Q4 FY2025ended Mar 31, 2025 | May 22, 2025before the open | – | – | – | Release |
| Q3 FY2025ended Dec 31, 2024 | Feb 12, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Sep 30, 2024 | Nov 12, 2024before the open | – | – | – | Release |
| Q1 FY2025ended Jun 30, 2024 | Aug 8, 2024before the open | – | – | -$0.78 | Release |
| Q4 FY2024ended Mar 31, 2024 | May 16, 2024before the open | – | – | – | Release |
| Q3 FY2024ended Dec 31, 2023 | Feb 8, 2024before the open | – | – | -$0.77 | Release |
| Q2 FY2024ended Sep 30, 2023 | Nov 7, 2023before the open | – | – | -$0.90 | Release |
| Q1 FY2024ended Jun 30, 2023 | Aug 3, 2023before the open | – | – | -$0.75 | Release |
| Q4 FY2023ended Mar 31, 2023 | May 18, 2023before the open | – | – | – | Release |
| Q3 FY2023ended Dec 31, 2022 | Feb 9, 2023before the open | – | – | -$0.69 | Release |
| Q2 FY2023ended Sep 30, 2022 | Nov 3, 2022before the open | – | – | -$0.79 | Release |
| Q1 FY2023ended Jun 30, 2022 | Aug 4, 2022before the open | – | – | -$0.78 | Release |
| Q4 FY2022ended Mar 31, 2022 | May 19, 2022before the open | – | – | – | Release |
| Q3 FY2022ended Dec 31, 2021 | Feb 3, 2022before the open | – | – | -$0.57 | Release |
| Q2 FY2022ended Sep 30, 2021 | Nov 4, 2021before the open | – | – | -$0.56 | Release |
| Q1 FY2022ended Jun 30, 2021 | Aug 6, 2021before the open | – | – | – | Filing |
| Q4 FY2021ended Mar 31, 2021 | May 20, 2021before the open | – | – | – | Filing |
| Q3 FY2021ended Dec 31, 2020 | Jan 11, 2021before the open | – | – | – | Filing |
| Q2 FY2021ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Replimune has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Replimune puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Replimune filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
- Update
- Results
- Update
- Update
- Update
- Results
- Update
- Results
- News
See a number that looks wrong?